Bukatina E E, Grigor'eva I V, Sokol'nik E I
Zh Nevropatol Psikhiatr Im S S Korsakova. 1991;91(9):53-8.
As many as 88 patients with Alzheimer's type senile dementia were followed up. Of these, 28 patients suffered from marked and 60 from unpronounced dementia. 74 patients received amiridine and 14 made up a control group. Amiridine was administered per os in the daily doses 20, 40 and 60 mg. The treatment lasted up to 14 months. The follow-up studies included clinical observations and testing according to a specially devised scale. A double blind study was carried out together with examinations of the drug withdrawal effect and comparisons of the main and control groups. All the tests demonstrated amiridine to have a well-defined therapeutic effect in 30-46% of the patients. Cognitive functions and the general mental status of the patients continued improving or got stabilized for a long time (up to 14 months). The speech improved for a shorter period of time. Amiridine was found to produce a beneficial effect both at the initial and marked stages of the disease. The most significant results were attained in the patients with unmarked dementia. The treatment efficacy correlated well with the dose of amiridine.
对多达88例阿尔茨海默型老年痴呆患者进行了随访。其中，28例患者患有重度痴呆，60例患有轻度痴呆。74例患者接受了阿米三嗪治疗，14例组成对照组。阿米三嗪通过口服给药，每日剂量分别为20毫克、40毫克和60毫克。治疗持续了14个月。随访研究包括临床观察以及根据专门设计的量表进行测试。进行了双盲研究，并对停药效果进行了检查，同时对主要组和对照组进行了比较。所有测试表明，30%至46%的患者使用阿米三嗪有明确的治疗效果。患者的认知功能和总体精神状态持续改善或长时间保持稳定（长达14个月）。言语改善的时间较短。发现阿米三嗪在疾病的初始阶段和重度阶段均产生有益效果。在轻度痴呆患者中取得了最显著的结果。治疗效果与阿米三嗪的剂量密切相关。
